• If you are wondering whether Bio-Techne stock still offers value at around US$56.17, the recent share performance gives you a useful starting point but not the full story.
• The stock has risen 6.7% over the past week and 29.7% over the last 30 days, yet it is still down 5.8% year to date and has declined 27.3% over 3 years and 47.8% over 5 years, which can influence how investors think about both its upside potential and risk.
• Recent coverage of Bio-Techne has focused on its role in life sciences tools and reagents, and how investor sentiment can swing as the market reassesses companies exposed to research spending and healthcare trends. This context helps explain why the stock can move quickly over short periods, even when the longer term record has been weaker.
• Right now Bio-Techne has a valuation score of 0 out of 6. This article will walk through the different valuation methods behind that result, then finish with a broader way to think about what the stock might be worth over time.

Bio-Techne scores just 0/6 on our valuation checks. See what other red flags we found in the full valuation breakdown.

Approach 1: Bio-Techne Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow, or DCF, model takes estimated future cash flows, then discounts them back to today to arrive at an implied value per share. For Bio-Techne, the model used is a 2 Stage Free Cash Flow to Equity approach, which starts from the company’s current free cash flow and then applies higher growth in the earlier years before tapering off.

Bio-Techne is currently generating last twelve month free cash flow of about $252.48 million. Analyst and extrapolated estimates used in this model project free cash flow of $269.26 million in 2026 and $405.05 million by 2030, with later years based on Simply Wall St extrapolations beyond the analyst window. All of these future figures are discounted back to today in US dollars using the DCF framework.

Pulling those projections together, the model estimates an intrinsic value of about $51.00 per share. Compared with a recent share price around $56.17, the DCF indicates that Bio-Techne stock is trading about 10.1% above this estimate, which suggests the shares appear slightly expensive on this cash flow view.

Result: OVERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Bio-Techne may be overvalued by 10.1%. Discover 47 high quality undervalued stocks or create your own screener to find better value opportunities.

Approach 2: Bio-Techne Price vs Earnings

For a profitable company like Bio-Techne, the P/E ratio is a straightforward way to relate what you pay for the stock to the earnings it currently generates. Investors usually accept a higher P/E when they expect stronger earnings growth or see the business as lower risk, and prefer a lower P/E when growth expectations or perceived risks are weaker.

Bio-Techne currently trades on a P/E of 80.32x. That compares with a Life Sciences industry average P/E of 35.03x and a peer average of 64.46x, so the stock is valued more richly than both those benchmarks. To sharpen this view, Simply Wall St also calculates a proprietary “Fair Ratio,” which is the P/E that would be expected for Bio-Techne given factors such as its earnings growth profile, industry, profit margins, market cap and risk characteristics. In this case, the Fair Ratio is 24.49x, which is materially below the current P/E.

Because the actual P/E is well above this Fair Ratio, Bio-Techne stock screens as expensive on this earnings based approach.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 20 top founder-led companies.

Upgrade Your Decision Making: Choose your Bio-Techne Narrative

Earlier it was mentioned that there is an even better way to understand valuation. Narratives on Simply Wall St let you attach your own story about Bio-Techne, including assumptions on future revenue, earnings and margins, to a financial forecast that produces a Fair Value you can compare with the current price. This Fair Value updates automatically as fresh news or earnings arrive, and you can line it up alongside other investors on the Community page. For example, there may be a more optimistic view that sets fair value around US$76.00 versus a more cautious view closer to US$49.00. In this way you can see exactly how different perspectives on the same company translate into very different price expectations.

Do you think there's more to the story for Bio-Techne? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.